Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyEmerging therapeutic agents for lung cancerCross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentCheckpoint inhibitors in lung cancer: latest developments and clinical potentialStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumabCurrent state of immunotherapy for non-small cell lung cancer.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectivesPredictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Combination immunotherapy: a road map.Checkpoint Blockade in Lung Cancer and Mesothelioma.PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells.Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.The evolutionary nature of the cancer immunotherapy revolution.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.MEDI 4736 (durvalumab) in non-small cell lung cancer.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe role of neoantigens in response to immune checkpoint blockade.Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.Recent developments in the use of immunotherapy in non-small cell lung cancer.Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Immune-Related Adverse Events From Immune Checkpoint Inhibitors.Chemotherapy remains an essential element of personalized care for persons with lung cancers.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
P2860
Q26738359-649CA225-C978-4FCC-8C5E-AF7A75DED34CQ26741101-13AC83D6-E6DF-4144-9B59-D63160EAD69DQ26745516-3A4B1765-C346-4A45-B773-E15E567C8A50Q28070165-1C0C0B55-BF9C-43B0-8AB1-B8A058E7E544Q28076294-E7DF0903-DBD2-415C-9691-E8AF9DC12364Q28076467-086685F5-0896-4AC3-90F7-C6F0D7250BB5Q30274619-A9088BA1-9DAF-447C-9265-718946F50C8AQ33645595-412BC516-F1B7-4313-B3DD-C32B3DB3FA61Q33876861-3269DD32-2F02-4DC2-889D-A25699A19E88Q33884361-FE12029A-2C94-44A3-AE14-5F280F9867C6Q33890538-F286B4CE-CAB3-447F-B6BB-788B902C793CQ33913077-87AD8C79-760B-4DAD-9791-31EBD08ED517Q34545316-3251BD9F-23D5-431E-BF8D-0271613D0005Q34552128-C6EA605E-E8F1-4974-8859-2B2901F0D0F6Q36295004-7D3BCD3A-C2BD-41E6-8D34-A3CE19B792FEQ36363579-76DF3E2A-C6C6-4EBB-9E66-927C8E9B1B4CQ37584395-BCA9F7D4-8849-4BDE-8A48-3117BDA4AFDCQ37702430-B3074205-4B8D-4712-BF29-747381B22E17Q37708795-B4816269-3C25-463A-8191-7D1C7D9CACEBQ37739214-BC53E795-D398-4498-988D-27A3EAE81790Q38375220-014021A2-80A0-498C-B822-69DF89AB3EB3Q38629823-38E0FE0B-70C6-48C2-89B3-5F2D5F5FBA88Q38636430-AF003E9D-E216-4574-94C9-B1E6A2C0D027Q38638860-4D86EADE-CEE7-4F9F-8AEA-1C53B4509AE8Q38640845-D38A8DD3-5865-466B-AA36-BBB373066C5AQ38658050-457CC807-99F2-4E7B-9F4C-270D277E64DDQ38687631-2C1BED3E-FCA1-4A5A-BDB4-FDE83AB3C552Q38720801-9A1AC727-106D-421A-8392-261979D1B6E5Q38748974-D081BCD6-3B22-4EA9-8CDF-185F22C82F7EQ38798968-7E22E173-DBEB-486B-99B1-404DC1878E11Q38804812-28243846-A39F-452F-844B-235C46FED345Q38807704-1F9DA155-1F6B-4FE6-A4AD-664215C1E6DEQ38819349-3619A576-7D4B-401E-AEEC-88B504E0B7D8Q38826419-954AA8D7-09B0-4DBD-AD0F-E1E20B7D32DAQ38830398-9218D7CB-280B-439F-B30B-148C200A1CCFQ38832640-835B7761-99B2-4CA4-B33D-15667872A723Q38838014-8729E504-958D-4A29-954D-04CF9C2C76EEQ38870763-C1F84E7C-E548-4929-939B-5384DE1D21D0Q38899873-1D7B9A4C-C76F-402E-B06D-8D42DBCFDE31Q38916160-ECF35A56-8512-4D7C-8732-1CB83783208E
P2860
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Safety and antitumour activity ...... a multicentre, phase 1b study
@ast
Safety and antitumour activity ...... a multicentre, phase 1b study
@en
type
label
Safety and antitumour activity ...... a multicentre, phase 1b study
@ast
Safety and antitumour activity ...... a multicentre, phase 1b study
@en
prefLabel
Safety and antitumour activity ...... a multicentre, phase 1b study
@ast
Safety and antitumour activity ...... a multicentre, phase 1b study
@en
P2093
P2860
P1433
P1476
Safety and antitumour activity ...... a multicentre, phase 1b study
@en
P2093
Ani Balmanoukian
Ashok Gupta
Jamie E Chaft
Joyson J Karakunnel
Keith Steele
Naiyer A Rizvi
Rachel E Sanborn
Rajesh Narwal
Sarah B Goldberg
Scott Antonia
P2860
P304
P356
10.1016/S1470-2045(15)00544-6
P577
2016-02-05T00:00:00Z